Strides Pharma Science Limited — Others, 11-07-2025: Shareholders meeting

Strides Pharma Science Limited has announced a board meeting on August 7, 2025, to consider the financial results for the quarter and half-year. The company recommends a final dividend of Rs. 4 per equity share for FY25, subject to shareholder approval. Key corporate actions during the year include the demerger of its CDMO and Soft Gelatin business into OneSource Specialty Pharma Limited, unlocking incremental shareholder value of approximately Rs. 78,800 million. The company also completed the amalgamation of Strides Alathur Private Limited and acquired full ownership of Strides Global Consumer Healthcare Limited, UK, and Amexel Pte. Ltd., Singapore. Strides reported consolidated revenue growth of 17.2% to Rs. 45,653 million and EBITDA growth of 36.8% to Rs. 8,028 million, with a net debt to EBITDA ratio improving to 1.9x. The US business grew 21.8% YoY to US$ 291 million, driven by new product launches and strong execution. The company maintains a diversified global presence with seven manufacturing sites across four continents, including four USFDA-approved facilities. Strides continues to focus on portfolio optimization, regulatory compliance, and ESG initiatives, achieving a strong ESG rating of 76/100 from S&P Global. The board comprises eight directors, including five independent directors and two women, with Mr. Aditya Arun Kumar retiring by rotation and offering himself for reappointment. The company has appointed M/s V. Sreedharan & Associates as secretarial auditors for five years starting FY26 and approved remuneration for cost auditors for FY26. No material litigation or regulatory non-compliance was reported, and internal financial controls were found adequate and effective. The company encourages shareholders to update their KYC details and participate in e-voting for the AGM.